BioPharma Dive – AI / Data
Lilly’s three-pronged obesity drug hits goal in large diabetes trial
BioPharma Dive – AI / Data
AstraZeneca lung drug gets ‘surprise’ win in COPD trials

The treatment, tozorakimab, succeeded where other similar therapies failed and could help a broader group of COPD patients than Dupixent.
BioPharma Dive – AI / Data
Novartis targets Xolair successor in buyout of startup Excellergy

Worth up to $2 billion, the deal is centered around a drug that could lead to faster and more complete control of allergic conditions than Novartis and Roche’s popular medicine.
BioPharma Dive – AI / Data
Rocket gene therapy cleared by FDA for rare immune disorder
Though the therapy, Kresladi, isn’t seen as a big seller, its clearance is a step forward for a company that’s lost most of its value since 2021 amid several setbacks.
-
Uncategorized9 years agoThese ’90s fashion trends are making a comeback in 2017
-
Contributors9 years agoThe final 6 ‘Game of Thrones’ episodes might feel like a full season
-
Uncategorized9 years agoAccording to Dior Couture, this taboo fashion accessory is back
-
Uncategorized9 years agoThe old and New Edition cast comes together to perform
-
Uncategorized9 years agoPhillies’ Aaron Altherr makes mind-boggling barehanded play
-
Uncategorized9 years agoUber and Lyft are finally available in all of New York State
-
Uncategorized9 years agoDisney’s live-action Aladdin finally finds its stars
-
Uncategorized9 years agoSteph Curry finally got the contract he deserves from the Warriors
